Furthermore, studies have revealed that FBXL5 acts as an oncogene in CRC progression by regulating the PTEN/PI3K/AKT signaling pathway in CRC tissues and cell lines [49]. This evidence concerns the gene FBXL5 and colorectal carcinoma.